FDA aligns with Cognition on a phase 3 zervimesine trial for Lewy body dementia, testing 100 mg daily for 9 months to target hallucinations.
News|Articles|January 6, 2025
Presenting Our January Theme: Cognition
Author(s)Leah Kuntz
Listen
0:00 / 0:00
Key Takeaways
- Addressing cognitive impairment in schizophrenia is essential for managing negative symptoms effectively.
- Innovative treatment strategies are necessary to combat cognitive deficits in psychiatric practice.
Do you want to be featured in a future Special Report? Check out our January theme!
Advertisement
Psychiatric Times is featuring monthly themes that speak to various aspects of psychiatry and issues relevant to psychiatric clinicians. Our January theme takes a look at a critical issue: Cognition. How do you combat negative symptoms of schizophrenia like cognitive impairment? What treatment strategies do you utilize?
If you have something you want to share, whether that's an article, case study example, or CME article, let us know! Write to us now at
Advertisement
Related to this article
Sleep disruption fuels Alzheimer risk via apnea, fragmentation, and inflammation; improving consolidated sleep, medication review, and sleep-specialist teamwork may protect cognition.
UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.
When an antidepressant seems to stop working, the patient’s deterioration is real. The explanation may be less certain.
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
A psychiatry resident and APA Diversity Leadership Fellow explains how social history, open talk about stigma, and bilingual videos can widen access to care.
Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.
Explore evolving ethical challenges of long-acting injectable antipsychotics, weighing relapse prevention against coercion, stigma, incentives, and racial equity in clinical practice.
Advertisement
Advertisement
Trending on Psychiatric Times
1
When Antidepressants Stop Working: Understanding Tachyphylaxis in Clinical Practice
2
Evidence-Based Ethical Principles for Long-Acting Injectable Antipsychotic Use
3
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
4
Sleep Disruption and Alzheimer Disease: A Bidirectional, Treatable Relationship
5